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Abstract
Currently, there is no effective vaccine to halt HIV transmission. However, pre-exposure pro-
phylaxis (PrEP) with the drug combination Truvada can substantially decrease HIV trans-
mission in individuals at risk. Despite its benefits, Truvada-based PrEP is expensive and
needs to be taken once-daily, which often leads to inadequate adherence and incomplete
protection. These deficits may be overcome by next-generation PrEP regimen, including
currently investigated long-acting formulations, or patent-expired drugs. However, poor
translatability of animal- and ex vivo/in vitro experiments, and the necessity to conduct long-
term (several years) human trials involving considerable sample sizes (N>1000 individuals)
are major obstacles to rationalize drug-candidate selection. We developed a prophylaxis
modelling tool that mechanistically considers the mode-of-action of all available drugs. We
used the tool to screen antivirals for their prophylactic utility and identify lower bound effec-
tive concentrations that can guide dose selection in PrEP trials. While in vitro measurable
drug potency usually guides PrEP trial design, we found that it may over-predict PrEP
potency for all drug classes except reverse transcriptase inhibitors. While most drugs dis-
played graded concentration-prophylaxis profiles, protease inhibitors tended to switch
between none- and complete protection. While several treatment-approved drugs could be
ruled out as PrEP candidates based on lack-of-prophylactic efficacy, darunavir, efavirenz,
nevirapine, etravirine and rilpivirine could more potently prevent infection than existing PrEP
regimen (Truvada). Notably, some drugs from this candidate set are patent-expired and cur-
rently neglected for PrEP repurposing. A next step is to further trim this candidate set by rul-
ing out compounds with ominous safety profiles, to assess different administration schemes
in silico and to test the remaining candidates in human trials.
Author summary
Pre-exposure prophylaxis (PrEP) is a novel, promising strategy to halt HIV transmission.
PrEP with Truvada can substantially decrease the risk of infection. However, individuals
often inadequately adhere to the once-daily regimen and the drug is expensive. These
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shortcomings may be overcome by next-generation PrEP compounds, including long-
acting formulations. However, poor translatability of animal- and ex vivo/in vitro experi-
ments, and difficulties in conducting long-term trials involving considerable sample sizes
(N > 1000 individuals) make drug-candidate selection and optimization of administra-
tion schemes costly and often infeasible. We developed a simulation tool that mechanisti-
cally considers the mode-of-action of all antivirals. We used the tool to screen all available
antivirals for their prophylactic utility and identified lower bound effective concentrations
for designing PrEP dosing regimen in clinical trials. We found that in vitro measured
drug potency may over-predict PrEP potency, for all antiviral classes except reverse tran-
scriptase inhibitors. We could rule out a number of antivirals for PrEP repurposing and
predicted that darunavir, efavirenz, nevirapine, etravirine and rilpivirine provide com-
plete protection at clinically relevant concentrations. Further trimming of this candidate
set by compound-safety and by assessing different implementation schemes is envisaged.
Introduction
Pre-exposure prophylaxis (PrEP) to prevent HIV infection (using drugs which are licensed for
its treatment) has been assessed in people at high risk of sexual transmission. Of the available
agents, once-daily tenofovir and emtricitabine (Truvada) have been extensively studied, and
demonstrate protective efficacy (59–100% [1, 2]) in individuals who are adherent to the medi-
cation; conversely poor medication adherence explains the lack of protection observed in
some trials [3]. However, major shortcomings of Truvada-based PrEP are its costs [4], a resid-
ual infection risk and the necessity for daily drug intake (which often leads to inadequate
adherence). These deficits may be overcome by next-generation PrEP regimen, including pat-
ent-expired antivirals and long-acting formulations.
Studies assessing next-generation PrEP regimen are underway [5], but rational selection of
which agents to advance into PrEP trials based on their intrinsic pharmacology and mode of
action has not been comprehensively or systematically undertaken. Moreover, studies have
focussed on patent-protected compounds [6], which are likely unaffordable in resource-con-
strained settings [4] hit hardest by the epidemic.
The considerable sample sizes (N> 1000 individuals) and clinical trial duration required
(years) to test any new candidate against tenofovir-emtricitabine, and the need to assess regi-
mens with forgiveness for missed dosing or episodic, event-driven PrEP make the current
strategy of empirical drug selection costly and prone to failure. We chose to explore an alterna-
tive strategy by developing a mathematical modelling tool to assess the per-contact efficacy of
anti-HIV drugs. This approach allows prediction of prophylactic utility by integrating drug
specific factors (pharmacokinetic/pharmacodynamic (PK/PD) attributes) and attributes of the
targeted risk group in order to probe and discard candidates, accelerate drug development and
markedly reduce costs. In this work, we are particularly interested in agents where existing pat-
ents had already, or are about to expire, in order to maximise the potential impact for low and
middle income countries.
Various epidemiological modelling approaches have been used to predict the public health
benefits of PrEP [7] and the risk of emergent drug resistance [8–10]. These approaches are
highly dependent on ad hoc parameter assumptions [11] (specifically the per-contact PrEP effi-
cacy), which may explain the different and contradictory predictions which have emerged.
Knowledge of the per-contact PrEP efficacy, ideally concentration-prophylaxis relation-
ships, are currently lacking and parameters derived from animal models poorly translate into
Drug-class specific utility of antiretrovirals for HIV prophylaxis
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human efficacy. Concentration-prophylaxis relationships are particularly critical to define
lower concentrations in human trials that can attain e.g.> 90% protection: I.e., ideally a PrEP
candidate should be dosed such that the concentrations stay above this target (e.g. 90% protec-
tion) and at the same time avoid adverse effects in all individuals. For prophylaxis, there is a
general void of information regarding drug-specific and drug-class specific concentration-pro-
phylaxis relationships. While the potency of drugs to inhibit HIV replication can readily be
measured in vitro, researchers are often unaware that this measure of drug potency may not
coincide with the potency to prevent HIV infection (prophylactic potency) and consequently
PrEP trial design may be flawed, incurring costs and putting individuals at risk.
In a top-down approach, Hendrix et al. [12] analyzed available clinical data for Truvada to
define concentration-prophylaxis relationships. However, this approach is naturally limited to
PrEP candidates where sufficient clinical data already exists and is not able to disentangle the
potency of the administered drugs from confounding factors. More mechanistic, bottom-up
approaches integrate various host- and viral factors [13–18] to predict the probability of viral
extinction. Despite their advantages, these approaches conventionally do not establish concen-
tration-prophylaxis relations, or they are specific to particular drugs [17] or drug classes [18].
In this work, we will first analyze the drug-class specific relation between in vitro potency
and PrEP efficacy and its dependency on the amount- and type of transmitted virus. Utilizing
pharmacokinetic and pharmacodynamic data for all treatment-approved drugs, and simulat-
ing typical viral exposures during sexual contact, we will then screen all treatment-approved
drugs for their PrEP utility and assess the sensitivity of the prophylactic endpoint with regard
to uncertainties in viral dynamics parameters and with regard to variabilities in drug concen-
tration, which can typically result from inter-individual metabolic differences or differences in
medication adherence. Our central aim is to provide a tool to screen out drug candidates with
a lack of- or uncertain prophylactic efficacy.
Methods
Before HIV infection is irreversibly established, viral replication is highly stochastic [19], cor-
roborated by the observation of a low transmission probability per exposure [20, 21] and a low
number of founder viruses responsible for establishing infection [22–25]. The stochasticity can
be explained by the order in which viral dynamics reactions occur: For example, when a single
virus comes into proximity of target cells, it may either be cleared or it may infect the target
cell which can eventually lead to systemic infection. In the current work, we will make use of
branching process theory [26] to derive analytical solutions for the probability of viral extinc-
tion [13, 15], i.e. the probability to hit the absorbing state where all viral compartments go
extinct. These solutions can be used directly to benchmark antivirals for their potential to
prevent infection as exemplified in the current work, or they can be used to design efficient
algorithms for the numerically exact simulation of complex prophylactic dosing regimen as
proposed in a related article [27].
Prophylactic efficacy
The infection probability PI(Y0) for some initial state Y0 is the complement of the extinction
probability PE(Y0)
PIðY0Þ ¼ 1   PEðY0Þ; ð1Þ
where Y0 denotes the initial viral population in a replication enabling (target-cell) environ-
ment. Throughout the article we will use Y = [V, T1, T2]T, i.e. the state of the viral dynamics is
defined by infectious viruses, early- and productively infected cells as outlined below. The
Drug-class specific utility of antiretrovirals for HIV prophylaxis
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for t!1. In words, the probability that all viral compartments will eventually go extinct. The
prophylactic efficacy φ then denotes the reduction in infection probability per contact,
φ ¼ 1  
PIðY0jDÞ
PIðY0j⌀Þ
ðprophylactic efficacyÞ; ð3Þ
where PI(Y0|D) and PI(Y0|⌀) denote the infection probabilities in the presence- and absence
of prophylactic drugs D respectively. The term PI(Y0|D) was computed using a mathematical
model of the viral dynamics (below) and by mechanistically considering the direct effects of
the distinct antivirals on viral replication whereas PI(Y0|⌀) is computed analogously, assuming
the absence of drug D = 0.
Drug-class specific direct effects on virus replication
Virus replication dynamics. We adopted the viral dynamics model described in [28, 29].
Although this model is a coarse representation of the molecular events happening during virus
replication, it allows to accurately and mechanistically describe the effect of all existing antire-
troviral drug classes on viral replication, as demonstrated in e.g. [30], and can be parameter-
ized by available in vitro and clinical data. Unlike the original model [28, 29] we do not
consider macrophages, motivated by the observation that transmitted viruses are not macro-
phage-tropic [31, 32] and in line with related modelling approaches [13, 14, 33–35]. The
model is schematically depicted in Fig 1. The modelled viral replication cycle consists of free
infectious viruses, uninfected T-cells, early infected T-cells (T1) and productively infected T-
cells (T2). Early infected T-cells (T1) and productively infected T-cells (T2) denote T-cells
prior- and after proviral integration respectively, where the latter produces virus progeny. The
term Tu = λT/δT denotes the steady state level of uninfected T-cells prior to virus challenge,
where λT denotes the birth and δT the death rate of uninfected T-cells. During the onset of
infection the number viruses are relatively low and the number of uninfected T-cells is fairly
unaffected by virus dynamics [33, 36]. Thus, for all computations, we consider the number of
uninfected T-cells to be constant, in line with related approaches [14, 15]. The dynamics of the
stochastic viral replication model after virus exposure are then defined by six reactions. In
absence of antivirals⌀ we have
a1ð⌀Þ ¼ ðCLþ CLT � TuÞ � V ðclearance of free virus; V ! �Þ ð4Þ
a2ð⌀Þ ¼ ðdPIC þ dT1Þ � T1 ðclearance of early infected cell; T1 ! �Þ ð5Þ
a3ð⌀Þ ¼ dT2 � T2 ðclearance of late infected cell; T2 ! �Þ ð6Þ
a4ð⌀Þ ¼ b � Tu � V ðsuccessful infection of a suscept: cell; V ! T1Þ ð7Þ
Drug-class specific utility of antiretrovirals for HIV prophylaxis
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a5ð⌀Þ ¼ k � T1 ðproviral integration; T1 ! T2Þ ð8Þ
a6ð⌀Þ ¼ NT � T2 ðproduction of infectious virus; T2 ! Vþ T2Þ; ð9Þ
with CLT ¼
1
rrev;⌀
  1
� �
� b in Eq (4) as outlined in [28] where ρrev,⌀ = 0.5 denotes the proba-
bility to successfully complete reverse transcription in the absence of inhibitors [37, 38]. Free
viruses are cleared by the immune system with a rate constant CL. Further, free viruses can be
also cleared during unsuccessful T-cell infection CLT through the destruction of essential viral
components of the reverse transcription-, or pre-integration complex intracellularly after the
virus entered the cell [37, 38]. The term β represents the lumped rate of infection of T-cells,
including the processes of virus attachment to the cell, fusion and reverse transcription, lead-
ing to an early infected cell T1, before proviral integration. Similarly, the term k denotes the
rate by which early infected T1 cells are transformed into productively infected T2 cells, involv-
ing proviral integration and cellular reprogramming. The term NT denotes the rate of produc-
tion of infectious virus progeny by productively infected T2 cells (infectious burst size). The
terms dT1 < dT2 denote the rates of clearance of T1 and T2 cells respectively and δPIC denotes
the rate of intracellular destruction of the pre-integration complex. Parameters for the viral
model are summarized in Table 1 and a mechanistic derivation of the dynamics from first
principles is given in [28] (Supplementary Text therein).
Class-specific direct drug effects. The direct effect of drugs D 2 {RTI, CRA, InI, PI} on
their target process is typically modelled using the Emax-equation [39]
ZDðtÞ ¼
Dmt
ICm
50
þ Dmt
; ð10Þ
where Dt is the target site concentration of the drug and the term IC50 and m denote the drug
Fig 1. Schematic of the HIV replication cycle and mechanism of interference by treatment-approved drug classes.
Free viruses are cleared by the immune system with a rate constant CL. Further, free viruses can be also cleared during
unsuccessful T-cell infection CLT through the destruction of essential viral components of the reverse transcription-,
or pre-integration complex [37, 38]. The term β represents the lumped rate of infection of T-cells, including the
processes of virus attachment to the cell, fusion and reverse transcription, leading to an early infected cell T1, before
proviral integration. Similarly, the term k denotes the rate by which early infected T1 cells are transformed into
productively infected T2 cells, involving proviral integration and cellular reprogramming. The term NT denotes the
rate of production of infectious virus progeny by productively infected T2 cells. The rates β, CLT, k and NT may be
modified by different antiretrovirals as indicated by bars (inhibition) and pointers with plus sign (drug-dependent
increase). The terms dT1 < dT2 denote the rates of clearance of T1 and T2 cells respectively and δPIC denotes the rate of
intracellular destruction of the pre-integration complex. CRA: Co-receptor antagonists, RTIs: reverse transcriptase
inhibitors, InIs: Integrase inhibitors, PIs: Protease inhibitors.
https://doi.org/10.1371/journal.pcbi.1006740.g001
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concentration at which the targeted process is inhibited by 50% and a hill coefficient [40]
respectively. In the current article we will assume that drug concentrations stay constant over
the course of infection, which allows to study drug- and drug class specific properties with
regard to prophylaxis. This assumption is overcome in related article [27], where pharmacoki-
netic inputs are explicitly considered to evaluate particular prophylactic dosing regimen.
Reverse transcriptase inhibitors. In the presence of reverse transcriptase inhibitors RTI
the reaction propensities a1 and a4 are affected [28], i.e.
a1ðRTIÞ ¼ CLþ
1
rrev;⌀
  ð1   ZRTIÞ
 !
� b � Tu
 !
� V ð11Þ
a4ðRTIÞ ¼ ð1   ZRTIÞ � b � Tu � V ð12Þ
where ηRTI 2 [0, 1] follows from Eq (10). Eq (11) results from the specific action of reverse
transcriptase inhibitors: they act only after irreversible fusion of viral particles and release of
viral contents has occurred by halting reverse transcription, which increases the probability
that essential viral constituents get cleared intracellularly preventing viral replication to prog-
ress. Thus, inhibition by RTIs can lead to an increase of cell-dependent clearance of viral parti-
cles as modelled in Eq (11) (see Supplementary Information of [28] for an explicit derivation).
From the equations it becomes evident that the increase in cell-dependent clearance (effect on
a1) matches the reduction in successful infection (effect on a4). The validity of this model has
been assessed in [30].
Other inhibitor classes. Co-receptor antagonists (CRA) decrease the infection propensity
a4 and a1, whereas integrase inhibitors InI decrease a5 and protease inhibitors PI reduce a6
respectively by a factor (1 − ηD) [28]:
a1ðCRAÞ ¼ CLþ ð1   ZCRAÞ �
1
rrev;⌀
  1
 !
� b � Tu
 !
� V ð13Þ
a4ðCRAÞ ¼ ð1   ZCRAÞ � b � Tu � V ð14Þ
a5ðInIÞ ¼ ð1   ZInIÞ � k � T1 ð15Þ
a6ðPIÞ ¼ ð1   ZPIÞ � NT � T2 ð16Þ
Note that unlike RTIs, CRAs decrease the adsorption of viral particles by cells, which does not
per se lead to a cell-dependent clearance of viral particles as in the case of RTIs. InIs block pro-
viral integration, affecting a5 and PIs prevent maturation, which lowers the amount of infec-
tious viruses produced.
Probability of virus extinction
For the ease of notation we introduce the unit vectors bV, bT1 and
bT2 which represent the states
where only one infected compartment is present (either virus, early- or late infected cells)
bV ¼
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While free virus is typically transmitted, our framework also allows to study prophylactic
efficacy for arbitrary initial states. Using the notation above, any state of the system can be
expressed as a linear combination of the unit vectors above. For example, 5 � bV � 3 � bT1 � 12 �
bT2 denotes the state where we have 5 viruses, 3 early infected cells and 12 late infected cells. In
S1 Text we provide a detailed derivation of infection/extinction probabilities after viral expo-
sure. Herein, we will provide a sketch of the central idea.
Starting from a single virus Y0 ¼ bV, we can write the Chapman-Kolmogorov equation:
PEðY0 ¼ bVÞ ¼
X1
n¼0
PðYr ¼ n � bVjY0 ¼ bVÞ � PEðYr ¼ bVÞ
n
: ð18Þ
In words, the extinction probability PEðY0 ¼ bVÞ is given by the probability that n viruses are
produced in a single replication cycle r, PðYr ¼ n � bVjY0 ¼ bVÞ, and that all of these viruses
eventually go extinct, considering all possible values of n. Herein we assumed statistical
independence, i.e. PEðYr ¼ n � bVÞ ¼ PEðYr ¼ bVÞ
n
. Furthermore, the extinction probabilities
for parent- and progeny virus are identical when the inhibitor efficacy is constant, i.e.
PEðY0 ¼ bVÞ ¼ PEðYr ¼ bVÞ. Next, we construct the embedded Markov chain [26]
corresponding from the continuous-time Markov jump model depicted in Fig 1 with
parameters in Table 1 (details in S1 Text). This allows to derive algebraic formulas for
PðYr ¼ n � bVjY0 ¼ bVÞ; n ¼ 0 . . .1. Substituting these into Eq (18), rearranging and solv-
ing for PEðY0 ¼ bVÞ yields a quadratic formula. Solving the quadratic formula, and using
PE(�) = 1 − PI(�) we derive analytical solutions for the infection probabilities after exposure
to a single virus bV, early- bT1 and late infected cell
bT2:
PIðY0 ¼ bVÞ ¼ max 0;
a4ðDÞ
a1ðDÞ þ a4ðDÞ
�
a5ðDÞ
a2 þ a5ðDÞ
1  
1
R0ðDÞ
� �� �
ð19Þ
PIðY0 ¼ bT1Þ ¼ max 0;
a5ðDÞ
a2 þ a5ðDÞ
� 1  
1
R0ðDÞ
� �� �
ð20Þ
PIðY0 ¼ bT2Þ ¼ max 0; 1  
1
R0ðDÞ
� �
: ð21Þ
where R0(D) denotes the basic reproductive number, i.e. the average number of viruses pro-
duced from a single founder virus [41] in a single replication cycle under the action of drug
D. Using our model we have R0ðDÞ ¼
a4ðDÞ
a1ðDÞþa4ðDÞ
�
a5ðDÞ
a2þa5ðDÞ
�
a6ðDÞ
a3
. The first solution PI(�) = 0 of
Table 1. Parameters generally used for the viral dynamics model. Excerpt from [28], except for CL(naive), which assumed that virus clearance is smaller in virus-naive
individuals compared to infected individuals, in line with [17, 72]. All parameters refer to the absence of drug treatment⌀. All parameters in units [1/day], except for λ
[cells/day] and β [1/day/virus]. Parameter sensitivity was assessed in S2 Text.
Parameter Value Reference Parameter Value Reference
λT 2�10
9 [78] k 0.35 [38]
dT; dT1 0.02 [79] β 8�10
−12 [80]
dT2 1 [81] NT 670 [28, 79]
δPIC 0.35 [38, 82] CL(naive) 2.3 [14, 33]
https://doi.org/10.1371/journal.pcbi.1006740.t001
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Eqs (19)–(21) are valid in the regimen where R0(D) � 1, i.e. in the regimen where extinction
is certain. The second solution describes the case where infection may occur, i.e. R0(D) > 1.
The pre-terms in the second solution of Eqs (19) and (20) denote the bottlenecking proba-
bilities that a late-infected, virus producing cell is reached, starting from a free virus (Eq
(19)) or starting from an early infected cell (Eq (20)) respectively.
We can assume statistical independence during the onset of infection (i.e. competition for
target cells is negligible) as noted before. Hence, for any given combination of free virus, early-
stage infected cell and late-stage infected cell the extinction probability is given by
PE Y0 ¼
V
T1
T2
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6
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@
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C
C
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¼
�
PEðY0 ¼ bVÞ
�V
�
�
PEðY0 ¼ bT1Þ
�T1
�
�
PEðY0 ¼ bT2Þ
�T2
; ð22Þ
where the exponents V, T1 and T2 denote the number of free virus, early- and late-stage
infected cells present and where we notice that PE(�) = 1 − PI(�).
Virus exposure model
Initial viral exposure after sexual intercourse occurs at tissue sites typically not receptive for
establishing and shedding HIV infection (e.g. mucosal tissues). Hence, the virus needs to pass
several bottlenecks and physiological barriers to reach a replication enabling (target-cell) envi-
ronment where infection can be established and from where it can shed systemically [42]. To
determine realistic inoculum sizes after sexual exposure to HIV, we previously developed a
data-driven statistical model linking plasma viremia in a transmitter to the initial viral popula-
tion Y0 in a replication-enabling environment [18] (Supplementary Note 4 therein for details).
Herein, we used the ‘exposure model’ to compute drug efficacy estimates after homosexual
exposure presented in section Prophylactic efficacy of treatment-approved antivirals. In brief,
this ‘exposure model’ was developed to capture key clinical observations: (i) the average HIV
transmission probabilities per exposure as reported in [20, 21, 43]. (ii) the fact that viral loads
in the untreated transmitter population are approximately log-normal distributed [18, 44–46]
(μ = 4.51, σ = 0.98) and (iii) the observation that the plasma viremia in the transmitter is the
most dominant factor determining HIV transmission [44, 47–49]. More specifically, it was
reported that each 10-fold increase in the transmitter’s viral load increases the transmission
probability per coitus by approximately 2.45-fold [47] (similar values confirmed in [49]). The
aforementioned clinical observations can be summarised in the formula below:
�P trans ¼
Z 1
n¼0
PðVL ¼ nÞ �
X1
n¼0
PðY0 ¼ n � bVjVL ¼ nÞ � PIðY0 ¼ n � bVÞ
 !
ð23Þ
where �Ptrans is the average transmission probability per exposure/coitus (given in (i)), P(VL = ν)
is the probability density of viral load in the donor (log-normal distributed, given in (ii)),
PIðY0 ¼ n � bVÞ is the infection probability when n viruses reach a replication enabling
site (computed from the virus dynamics model above with PIðY0 ¼ bVÞ � 0:0996) and
PðY0 ¼ n � bVjVL ¼ nÞ denotes the ‘exposure model’ (the probability that n viruses reach a rep-
lication-enabling compartment after viral exposure from a transmitter with virus load ν). For
the ‘exposure model’, we assumed a binomial distribution
PðY0 ¼ n � bVjVL ¼ nÞ ¼
dnme
n
� �
� rn � ð1   rÞdn
me  nÞ
ð24Þ
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where m = log10 (2.45) is given by (iii) [47] and the success probability r was estimated in
a previous work [18] (Supplementary Note 4 therein), e.g. rhomo = 3.71 � 10−3 for homosex-
ual exposure. However, the model can be adapted to the different exposure types (e.g.
heterosexual, needle-stick, etc . . .). In this model, the success probability r summarises both
the extent of local exposure, as well as the probability of passing all bottlenecking physiolog-
ical barriers and reaching a replication enabling target cell compartment. Lastly, in line with
Keele et al. [22], we observed that if infection occurs in our model it is established by a very
low number of viruses after homosexual contact and usually by a single founder virus after
heterosexual contact.
Results
Relation between direct effects and prophylactic efficacy
Drug-specific inhibition of viral replication can be studied in vitro, for example in single-
round turnover experiments [40] or even more mechanistically using enzymatic assays in con-
junction with appropriate mathematical models [50]. Since the infection risk per exposure is
already low in untreated individuals [20, 21], exploring the prophylactic efficacy (reduction in
infection risk) in the clinic is difficult, requiring very long (several years) clinical trials with
many individuals (N> 1000) to achieve statistically evaluable results. Systematic evaluation of
concentration-effect relations is not feasible in this context, notwithstanding ethical concerns.
We wanted to gain a deeper insight how in vitro measurable direct drug efficacy η translates
into prophylactic efficacy φ (reduction in infection probability per exposure) in a drug-class
specific manner. Particularly, since different antiviral drug classes inhibit distinct stages in the
HIV replication cycle, we wanted to elucidate how these different mechanisms of action affect
prophylaxis. We combined Eqs (11)–(16) with Eqs (19)–(21) into Eq (3) to predict prophylac-
tic efficacy. When relating direct drug effects η to prophylactic efficacy φ we observed striking
drug-class specific differences as illustrated in Fig 2. Using parameters from Table 1 we found
that the prophylactic efficacy φ may be less than predicted by in vitro measurable direct drug
effects η. The sole exception are reverse transcriptase inhibitors (RTI) in case of exposure to a
single virus particle Y0 ¼ bV where the two measures of drug efficacy coincide. While the pro-
phylactic efficacy after exposure to a single virus are moderately less than the direct effects of
co-receptor antagonists CRA and integrase inhibitors InI respectively (Fig 2A), there is a pro-
found difference for protease inhibitors, which do not seem to reduce HIV transmission unless
their direct efficacy η exceeds� 95%. Interestingly, a similar observation using a different
mathematical model and only distinguishing RTIs and PIs has been made by Conway et al.
[13].
While HIV-transmission typically occurs after exposure to free virus, it is still useful to
study the prophylactic efficacy of distinct drug classes in the hypothetical case when infected
cells were present in the exposed individual. A realistic example for this scenario is post-
exposure prophylaxis (PEP): During PEP, drugs are taken shortly after virus exposure and
initial viral replication steps may have taken place generating early- or late infected cells. As
can be seen in Fig 2B and 2C, the prophylactic efficacy of all drugs profoundly deteriorates
compared to their direct effects, i.e. only very effective (in terms of η) drugs may prevent sys-
temic infection once cells become infected in the exposed individual. An exception are inte-
grase inhibitors: their prophylactic efficacy φ is moderately less than their direct effect η
(panel B) if only early infected cells T1 (before proviral integration) were present. Thus,
while the prophylactic efficacy of all other drug classes is profoundly less than their direct
effects once infected cells emerged, integrase inhibitors may still potently prevent infection.
An intuitive explanation for the deterioriation of prophylactic efficacy can be made in terms
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of changes in drug-target stoichiometry: For example, after exposure to a single virus bV,
drugs from the classes of CRAs, RTIs and InIs need to block a single reaction to foster viral
extinction. For PIs however, the same is only achieved if maturation of the entire viral prog-
eny is inhibited (possibly hundreds of particles). Similarly, when considering a single early
infected cell bT1, CRAs and RTIs can only prevent further viral expansion after viral progeny
has emerged. Subsequently, for each viral particle (possibly hundreds) the respective target
processes (receptor binding, reverse transcription) need to be blocked by the inhibitors.
Along the same lines of argumentation it is also evident that prophylactic efficacy is generally
more favourable in the case of PrEP, compared to post-exposure prophylaxis (PEP), where
initial viral replication may have occurred.
In vitro drug potency may overestimate PrEP potency
In vitro measured drug potency IC50, IC90 usually guides the design of PrEP trials [51]. In par-
ticular, dosing regimen are designed so that the majority of individuals achieve drug levels just
above the 90% inhibitory concentrations IC90. However, it has never been rigorously investi-
gated whether these ‘target concentrations’ are sufficient to provide 90% protection against
HIV infection. Integrating Eq (10) into Eqs (11)–(16), (19) and (3) allows to predict the con-
centration-prophylaxis profile for different HIV-1 inhibitor classes. Rearranging this compos-
ite equation reveals how in vitro measured drug potency IC50, IC90 can be translated into
prophylactic potency (50% and 90% reduction in infection risk, EC50 and EC90, respectively),
guiding clinical trial design. The derived analytical expressions for the prophylactic efficacy
(reduction in infection risk) indicate that the shape of the concentration-prophylaxis profile
varies considerably for different HIV-1 inhibitor classes with important consequences for their
prophylactic endpoints (% reduction in HIV transmissibility).
After exposure to a single virion Y0 ¼ bV, the overall shape of the concentration-prophylaxis
profile for co-receptor antagonists (CRAs), reverse transcriptase inhibitors (RTIs) and inte-
grase inhibitors (InIs) is a classical Emax equation (the equation of choice for evaluating
Fig 2. Relation between direct drug effect and prophylactic efficacy. The relation between direct drug effect η and prophylactic efficacy φ (reduction in infection) is
shown for different drug classes utilizing the viral model depicted in Fig 1 with parameters stated in Table 1. Panel A: Relation between η and φ when a single virus
Y0 ¼ bV reached a replication-enabling compartment in the virus-exposed individual. Panel B: Relation between η and φ when a single early infected cell Y0 ¼ bT1 or
(panel C) a late infected T-cell Y0 ¼ bT2 reached a replication-enabling compartment. Solid red lines: CRAs, solid green line: RTIs, dashed blue line: InI, dashed purple
line: PIs.
https://doi.org/10.1371/journal.pcbi.1006740.g002
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concentration-effect relations), see S1 Text for derivation.
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where D denotes the concentration of the drug in the blood plasma, m is a slope parameter
and IC50 denotes the plasma concentration of the drug that inhibits the targeted process (co-
receptor binding, reverse transcription or proviral integration) by 50 percent. This parameter
can typically be measured in vitro, e.g. using single-round turnover experiments [40] and is
stated in Table 2 for various drugs. Parameters u ¼
CL�rrev;⌀
CL�rrev;⌀þb�Tu
< 1 and W ¼
dPICþdT1
dPICþdT1
þk < 1
denote the respective probabilities, in the absence of drugs, that the virus is eliminated before
entering a host cell, and that essential virus compartments get cleared intracellularly after
reverse transcription and before provirus integration. The parameter EC50 denotes the plasma
concentration of the drug that decreases the probability of infection by 50%, i.e. the prophylac-
tic potency of the drug. R0(⌀) denotes the basic reproductive number in the absence of drugs,
i.e. the average number of viruses produced from a single founder virus [41] in a single replica-
tion cycle when no antivirals were present (R0(⌀)� 67 according to the utilized model).
When the target cell density is sufficiently high (herein considered as a target cell environ-
ment), we have R0(⌀)� 1 and hence the left-side scaling factor in Eqs (25)–(27) will be
close to one, R0(⌀)/(R0(⌀) − 1)� 1. An analysis with low target cell densities is provided in
S2 Text.
In case of exposure to a single virus particle bV, the slope parameters in the right-most equa-
tions coincide with the slope parameter for the respective drug-targeted process m (Eq (10)),
stated in Table 2. Notably, for RTIs, we have EC50� IC50, i.e. the drugs potency measured in
vitro in single-round turnover experiments [40] directly translates into its potency to prevent
infection. Using parameters from Table 1 we observe EC50 > IC50 for CRAs and InIs, i.e. com-
pared to their in vitro potency, they are less potent in preventing infection. This is largely due
to the respective factors ϑ−1, υ−1 > 1, compare Fig 3A–3C. For InIs this observation is robust
across a broad range of parameter values, as shown in S2 Text. Consequently, for InIs, higher
concentrations are required to prevent infection than suggested after conducting the respective
in vitro experiments. For CRAs, predictions are parameter dependent, S2 Text. Rearranging
Eqs (25)–(27) allows to directly compute the drug concentration that prevents infection with x
percent probability (the ECx) from the corresponding in vitro 50% inhibitory concentration
IC50 (derivations in S3 Text): In case of exposure to a single virus particle we get
ECx ¼ IC50 � F �
x
100 � C   x
� �1=m
; ð28Þ
where ECx is the drug concentration that achieves x percent of prophylactic efficacy and the
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term F� 1 is a drug class specific factor
F ¼
CLþ b�Tu
r
� �
=CL; for CRA
1; for RTI
1=W; for InI:
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ð29Þ
and
C≔
R0ð⌀Þ
R0ð⌀Þ   1
� 1; ð30Þ
if R0(⌀)� 1. Importantly, when exposure to multiple viruses occurs, the concentration-pro-
phylaxis profile is no longer an Emax equation for any inhibitor class, Fig 3A–3C. Further-
more, the slope parameter increases and the EC50 may exceed the in vitro measurable IC50
value. At large inoculum, the corresponding profiles become switch-like. For protease inhibi-
tors (PIs), we derive a power function to describe their prophylactic efficacy (mechanistic deri-
vation in S1 Text):
φðbVÞ ¼
1
R0ð⌀Þ   1
�
Dm
ICm
50
¼ C �
Dm
ICm
50
ðPIÞ for 0 � φ � 1; ð31Þ
Table 2. Pharmacodynamic and pharmacokinetic parameters. IC50 [nM] and m [unit less] values are available from single turnover experiments in primary peripheral
blood mononuclear cells supplemented with 50% human serum from Shen et al. [40], Laskey et al. [92] (DTG) and Jilek at al. [93] (MVC). Because some compounds are
highly protein bound, IC50 values had to be adjusted for protein binding as outlined in the S5 Text. Indicated values are after protein adjustment. IC50 values are reported
to be log normal distributed and m values to be normal distributed [40, 93] with respective coefficients of variation CV = 100 � σ/μ [%]. Parameters Cmin and Cmax refer to
the minimum and maximum concentrations in [nM] during chronic administration using the standard dosing regimen, taken from Shen et al. [40] except those for DTG
[94], RPV [95] and MVC [96] (150mg twice daily). t1/2—half life of the drug in [hr], fb—fraction of the drug bound to plasma proteins in [%]. +These values were fixed to
the typical parameter distributions observed for all other compounds. �Parameters were taken from Drug Bank when available https://www.drugbank.ca/, accession num-
bers: DB04835, DB00625, DB00238, DB00705, DB08864, DB06817, DB09101, DB08930, DB01072, DB00701, DB01264, DB00224, DB00220, DB00932 or [PubChem
https://pubchem.ncbi.nlm.nih.gov, id: 92727. When parameters were not readily available in these databases, parameters were obtained from the indicated literature
source. MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirine, ETR -etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir, DTG -dolutegravir,
ATV -atazanavir, APV -amprenavir, DRV -darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir.
Class Name IC50 (CV) m (CV) Cmin Cmax fb t1/2
CRA MVC 5.06 (290) 0.61 (27.9) 45 557 76� 14�
RTI EFV 10.7 (16.7) 1.69 (4.73) 5630 12968 99.4 [83] 40�
RTI NVP 116 (31.2) 1.55 (9.68) 10883 25153 60� 45�
RTI DLV 336 (44.7) 1.56 (11.5) 10672 27134 98 [84] 5.8�
RTI ETR 8.59 (16.3) 1.81 (12.7) 688 1617 99.9 [85] 35 [86]
RTI RPV 7.73 (17.9) 1.92 (10.4) 177 470 99.1� 44.5�
InI RAL 25.5 (12.1) 1.1 (4.55) 203 3996 83� 9�
InI EVG 55.6 (43.8) 0.95 (4.21) 301 1661 99� 8.7�
InI DTG 89.0 (25.3+) 1.3 (15.4+) 2918 8471 98.9� 14.5 [87]
PI ATV 23.9 (11.8) 2.69 (10.4) 899 6264 86 [88] 7�
PI APV 262 (12.6) 2.09 (6.70) 2870 14319 90� 7.1�
PI DRV 45.0 (21.6) 3.61 (8.86) 5081 14783 95 [85] 15�
PI IDV 130 (11.0) 4.53 (7.94) 1827 12508 60 [89] 1.8�
PI LPV 70.9 (20.1) 2.05 (5.85) 8757 15602 99 [60] 2.5[
PI NFV 327 (26.8) 1.81 (12.7) 2285 5104 98� 3.5�
PI SQV 88.0 (9.7) 3.68 (6.25) 897 13282 97 [90] 3.9 [91]
PI TPV 483 (18.0) 2.51 (14.3) 35598 77585 99.9� 5�
https://doi.org/10.1371/journal.pcbi.1006740.t002
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where C<< 1 is a constant. Moreover, for realistic (large) R0(⌀)� 3 their plasma concentra-
tion has to exceed their IC50 to decrease the probability of infection by at least 50%, Fig 3D.
Similarly, we can rearrange the equation above and obtain
ECx ¼ IC50 � G �
x
100
� �1=m
; ð32Þ
Fig 3. Shape of the concentration-prophylaxis profile. Colored lines depict the concentration-prophylaxis profile for an average drug class-specific slope parameter
�m in Eq (10). Solid colored line for an inoculum of one virus Y0 ¼ bV and dashed colored line for an inoculum of Y0 ¼ 100 � bV. Shaded areas indicate the
concentration-prophylaxis profile for the smallest mmin and largest class-specific slope parameter mmax for the respective drug class as indicated in Table 2. A: Co-
receptor antagonists. Currently only one co-receptor antagonist, maraviroc, is approved. We use �m ¼ mmin ¼ 0:61 and also plot mmax = 1 as a reference. B: Non-
nucleoside reverse transcriptase inhibitors (NNRTIs); �m ¼ 1:71, mmin = 1.55 and mmax = 1.92. Nucleoside reverse transcriptase inhibitors (NRTI) have been analyzed
in [18]. C: Integrase inhibitors, �m ¼ 1:12, mmin = 0.95 and mmax = 1.3. D: Protease inhibitors; �m ¼ 2:87, mmin = 1.81 and mmax = 4.53. Utilized virus dynamics
parameters are stated in Table 1.
https://doi.org/10.1371/journal.pcbi.1006740.g003
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for the exposure to a to a single virus, where G≔ R0(⌀) − 1. Again, in case of exposure to mul-
tiple viruses, the slope parameter and EC50 increase, making the prophylactic efficacy of PIs
exhibiting a switch-like behaviour as can be seen in Fig 3D. This switch-like behaviour makes
the prophylactic use of PIs vulnerable to non-adherence, as well as general variations in con-
centrations (e.g. pharmacokinetics, inter-individual variability), and the prophylactic efficacy
with these inhibitors may alternate between zero- or complete protection.
Prophylactic efficacy of treatment-approved antivirals
The combination of the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and
tenofovir (Truvada) is the only intervention approved for pre-exposure prophylaxis (PrEP).
According to our previous estimates [18], Truvada provides 96% protection in fully adherent
individuals, which is in line with clinical estimates of 86-100% protection in the IPERGAY
study [1], 58-96% in the PROUD study [2] and 96% in the Partners PrEP OLE study in appar-
ently highly adherent individuals. The VOICE [3] and FEM-PrEP [52] studies indicated that
Truvada may not prevent infection in poorly adherent individuals.
Currently, a number of drugs are under investigation for PrEP repurposing [6]. Notably, all
currently investigated compounds are patent-protected and may not be affordable in resource-
constrained countries hit hardest by the epidemic. In this work, we wanted to unselectively
assess the utility of treatment-approved antivirals for prophylaxis and to assess whether cur-
rently neglected (patent-expired) compounds may be cost-efficient alternatives to be further
explored in non-profit prophylaxis programmes.
We utilized comprehensive sets of drug-specific pharmacodynamic- and pharmacokinetic
parameters (Table 2) to parameterize Eq (10) and to predict the prophylactic efficacy of treat-
ment approved CRAs, non-nucleoside reverse transcriptase inhibitors (NNRTIs), InIs and PIs
at clinically relevant concentration ranges (the class of NRTIs have been analyzed in earlier
work [18]). Moreover, we sampled the extent of viral exposure (number of viruses transmitted
and reaching a replication-enabling compartment; Eq (22)) from a previously parameterized
distribution [18] that accurately reflects transmitter virus loads and drug-free infection proba-
bilities after sexual contact. The resultant benchmark is depicted in Fig 4. Fig 4 allows for an
initial screen of the utility of the various drugs for oral PrEP. Most analyzed drugs, except for
maraviroc (MVC), raltegravir (RAL), elvitegravir (EVG) and nelfinavir (NFV), potently pre-
vent infection at concentrations ranges typically encountered in fully adherent individuals
during treatment (range between minimum- to maximum concentration, [Cmin; Cmax]). Dur-
ing prophylaxis, adherence to the dosing regimen is a major problem and we thus consider a
lower bound concentration that would arise if the drug had not been taken for three days prior
to exposure Clow (thin dashed vertical line in Fig 4) to emphasise a ‘pharmacokinetic safety
margin’ in case of poor adherence. Numerical values for the computed maximum prophylactic
efficacy and the efficacy at the lower bound concentrations are reported in Table 3 alongside
with estimated EC50 and EC90 values. While in Table 3 we report the EC50 and EC90 values
after challenge with a single virus bV, the corresponding values after virus challenges sampled
from the distribution for homosexual exposure Eq (24) were almost identical, see S4 Text for a
comparison. Our simulations indicate a residual risk of infection for most analyzed drugs.
Notably, most protease inhibitors may confer anything from none- to absolute protection
within relevant concentration ranges, [Clow; Cmax], which highlights a severe limitation to their
PrEP use in the context of poor adherence or pharmacokinetic (intra-/inter individual) vari-
ability. An exception among this rule is darunavir (DRV), which is predicted to be almost fully
protective for the entire concentration range.
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Fig 4. Drug specific prophylactic efficacy. Solid and dashed colored lines depict the concentration-prophylaxis profile for the
individual drugs. The solid lines represent the concentration-prophylaxis profiles and light and dark grey areas indicate the quartile
ranges and 5-95% ranges of the concentration-prophylaxis profile, considering uncertainty in pharmacodynamic parameters
(Table 2) and the distribution of viral inoculum sizes after homosexual exposure to HIV using the virus exposure model’ (Methods
section and [18]). Maximum clinically achievable concentrations Cmax for chronic oral administration of the standard dosing
regimen and a lower bound concentration Clow that would be achieved if the last dose had been taken three days prior to virus
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Of the analyzed non-PI drugs, the NNRTIs efavirenz (EFV), nevirapine (NVP), etravirine
(ETR) and rilpivirine (RPV) are extremely potent with regard to prophylaxis: These drugs pre-
vent infection, even when the drug had not been taken for three consecutive days, Table 3.
Notably, NVP and EFV are patent-expired and may represent suitable candidates for use in
resource-constrained settings (price per day� 0.1US$). The co-receptor antagonist maraviroc
(MVC) and the integrase inhibitor dolutegravir (DTG) retain some prophylactic efficacy (50
and 72% respectively) at lower bound concentrations Clow. The CRA maraviroc (MVC), the
NNRTI rilpivirine (RPV) and the InI raltegravir (RAL) are currently investigated for use as
PrEP compounds (long-acting injections of RPV and RAL; oral- or topical application of
MVC). In our simulations the predicted PrEP efficacy of these drugs would drop to 8% (RAL)
and 50% (MVC) when the drug had not been taken for three consecutive days prior to virus
exposure. Notably, RPV remained 100% effective.
Lastly, we want to note that our predictions are based on viral dynamics parameters that
may under-predict prophylactic efficacy, as indicated in S2 Text. The main purpose of this
modelling study was to rule out drug candidates, based on lack-off- or uncertain- prophylactic
exposure are marked by thick and thin vertical black dashed lines respectively. For IDV, LPV, NFV and SQV Clow falls below the
range of the x-axis. Downward pointing arrows indicate minimum (pre-dose) concentrations achieved for standard regimen in
adherent individuals as reported in [40], [96] and [95]. MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirdine, ETR
-etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir, DTG -dolutegravir, ATV -atazanavir, APV -amprenavir, DRV
-darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir. �recently or currently tested for
PrEP.
https://doi.org/10.1371/journal.pcbi.1006740.g004
Table 3. Prophylactic efficacy and sensitivity to incomplete adherence. The table shows the prophylactic efficacy (% reduction in infection probability) of all investigated
drugs at their respective maximum achievable drug concentrations after chronic oral administration of the standard regimen and its efficacy at a concentration level that
would be reached if the last dose had been taken least three days prior to virus exposure Clow ¼ Cmin � e  2�24�ke , with ke = ln(2)/t1/2 and halflifes t1/2 reported in Table 2. The
5-95% range of these estimates are shown in brackets and consider uncertainty in pharmacodynamic parameters IC50, m and variability in virus exposure after homosexual
contact, according to the ‘virus exposure model’ (Methods section and Duwal et al. [18]. The last two columns show the EC50 and EC90 in the case when an individual was
exposed to a single virus bV. MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirdine, ETR -etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir,
DTG -dolutegravir, ATV -atazanavir, APV -amprenavir, DRV -darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir. �currently
investigated for PrEP.
prophylactic efficacy φ [%] EC50ðbVÞ EC90ðbVÞ
drug φ(Cmax) φ(Clow) [nM] [nM]
MVC� 96.10 (74.11;100) 50.12 (18.63;85.42) 11.45 349.63
EFV 100 (100;100) 100 (100;100) 10.55 36.23
NVP 100 (100;100) 100 (100;100) 114.06 438.06
DLV 100 (100;100) 3.38 (0.88;10.19) 329.50 1254.58
ETR 100 (100;100) 100 (100;100) 8.45 26.75
RPV� 100 (100;100) 100 (99.02;100) 7.61 22.55
RAL� 100 (100;100) 8.15 (6.32;10.23) 45.40 302.36
DTG� 100 (99.03;100) 72.12 (57.77;84.85) 145.18 722.23
EVG 94.61 (89.02;97.97) 6.96 (3.66;12.49) 108.66 976.25
ATV 100 (100;100) 0.08 (0.04;0.15) 87.44 108.79
APV 100 (100;100) 0.01 (0.01;0.03) 1394.96 1848
DRV� 100 (100;100) 100 (100;100) 118.32 139.24
IDV 100 (100;100) 0 (0;0) 280.80 319.71
LPV 100 (100;100) 0 (0;0) 389.69 519.09
NFV 100 (64.01;100) 0 (0;0) 2253.66 3118.34
SQV 100 (100;100) 0 (0;0) 227.29 266.66
TPV 100 (100;100) 0 (0;0.02) 1944.89 2458.09
https://doi.org/10.1371/journal.pcbi.1006740.t003
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efficacy. While some drugs’ prophylactic efficacy might be under-predicted, this conservative
choice of parameters provides a more solid scientific basis for the remaining candidates that
are predicted to be potent.
Discussion
Our intent was to develop a tool to screen out unsuitable candidates for PrEP based on unfa-
vourable pharmacokinetic and pharmacodynamic characteristics. Clearly, the attributes which
make any compound favourable extend beyond PK/PD, and critically also depend on tolera-
bility, ease of dosing, cost and acceptability. Nevertheless, screening antiretroviral agents based
on their intrinsic antiviral activity, mode of action, duration of efficacy beyond the dosing
interval, and tolerance for missed dosing is a logical starting point when assessing potential
candidates for PrEP.
Strikingly, we observed that in vitro measured drug potency may over-estimate PrEP
potency in a drug-class specific manner. For all non-RTI drugs dosing schedules in clinical
trials may have to be adjusted accordingly to reach the desired prophylaxis endpoints (% pro-
tection). We provide an easy-to-use software tool to determine the corresponding target con-
centrations (www.systems-pharmacology.org/prep-predictor).
For non-PI drugs, we observed a more graded relationship between their prophylactic effi-
cacy and drug concentrations. At low virus inoculum sizes, the slope of their concentration-
prophylaxis profile is largely determined by the slope coefficient that describes their direct
effects [40]. Notably, for PIs we observed a very steep concentration prophylaxis profile, sug-
gesting that within clinically relevant ranges for oral PrEP (Fig 4) their efficacy is likely to
switch between zero- and complete protection, in an ‘either-or’ scenario. This characteristic
renders PIs particularly vulnerable to poor adherence and drug-drug interactions. An intuitive
explanation for this steep concentration-prophylaxis profile of PIs (power function in Eq (31))
is based on its unfortunate drug-to-target stoichiometry: A single late infected cell T2 produces
hundreds of infectious viruses on average (using parameters from Table 1 a6/a3 = 670) and a
PI needs to prevent all of them from becoming infectious to fully prevent infection. By con-
trast, all other compounds only need to prevent a single viral entity from progressing, explain-
ing the proportionality to the EMAX equation seen in Eqs (25)–(27).
By screening all treatment-approved antivirals for their PrEP utility, we predicted that efa-
virenz (EFV), nevirapine (NVP), etravirine (ETR), rilpivirine (RPV) and darunavir (DRV)
may fully prevent infection after oral application and in case of poor adherence (Table 3 and
Fig 4). Notably, these compounds have favourable inhibitory quotients (clinically achieved
concentrations vastly exceed their EC50) and their long elimination half-lives guarantees that
inhibitory quotients stay in that favourable range. The drugs maraviroc (MVC) and dolutegra-
vir (DTG) potently prevent infection but may allow for HIV transmission when individuals
poorly adhere to the medication. Notably, the NNRTIs EFV, NVP, RPV and ETR exhibit long
elimination half-lives (30-40h) and achieve concentrations required for PrEP to act quickly,
and durably. However, there are some safety concerns with liver toxicity, which contraindicate
e.g. the use of NVP in uninfected individuals. Liver toxicity to ETR remains to be elucidated in
the context of prophylaxis. Skin reactions (ETR and EFV) and neuropsychiatric effects (EFV)
have been reported in the context of HIV treatment that need to be evaluated in the context of
potential PrEP applications. Likewise, skin reactions and rare liver toxicities with DRV need
careful assessment in the context of PrEP repurposing. Moreover, the particular concentra-
tion-prophylaxis profile, as depicted in Fig 4, argues for a form of DRV administration that is
not dependent on daily dosing for maintaining drug levels (e.g. slow release or nanoparticle
formulations). For rilpivirine (RPV), our simulations suggest that near complete protection
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can be achieved when concentrations exceed EC90, Fig 4. RPV is currently investigated as a
long-acting formulation in HPTN076 using 1200mg injections every 2 month which yields
tough concentrations (median 186 nM) well in excess of this target. However, significant vari-
ability is still observed related to gender, and between injections on different occasions [51]
which could be incorporated into future model generations. Besides rilpivirine, maraviroc
(MVC; 300mg once daily), and raltegravir (RAL) are currently clinically investigated for oral
PrEP. Our simulations suggest MVC may incompletely prevent infection even at maximum
concentrations and that its efficacy steadily drops with declining levels down to 50% when
the drug had not been taken for three days prior to exposure. Results from the NEXT-PrEP
(HPTN 069) phase II study observed that MVC may not be potent enough on its own and that
among those acquiring HIV infection, MVC concentrations were low, absent or variable [53].
Our model prediction is consistent with the reported lack of efficacy of MVC as PrEP in ani-
mals and human explant samples [54] and suggests that the potency of MVC, against infection
may be less than its potency in preventing HIV replication (EC50 > IC50, EC90 > IC90). How-
ever, EC50, EC90 estimates for co-receptor antagonists are highly parameter sensitive (S2 Text)
warranting further research into elucidating the early infection dynamics. Using the parame-
ters presented in Table 1, we estimate that the EC90 may be around 350nM, which is approxi-
mately 70 times larger than its IC50 (conversion formula provided in the results section).
Notably, during the dose finding for MVC an IC90 of only 3.9nM (2ng/ml) was considered
and this estimate was taken directly to determine target concentrations providing 90% prophy-
lactic efficacy. Other compounds currently under investigation (HPTN-083) [55], but not eval-
uated in our study are the novel long-acting integrase inhibitor cabotegravir.
Our model has several limitations, but also a number of important advantages. Our simula-
tions do not take into account drug concentrations at the site of mucosal exposure (e.g. cervix,
rectum) [51, 56]. These concentrations have, however, not been validated as targets for suc-
cessful prevention or treatment, whereas data exist (albeit limited) for plasma drug concentra-
tions. Instead, we modelled based on unbound concentrations, in line with the broadly
accepted ‘free drug hypothesis’. Under the ‘free drug hypothesis’, the unbound concentrations
are assumed to be available at the target site to exert pharmacological effects. For drugs highly
bound to plasma protein (> 90%), naturally, their total concentrations at sites other than the
plasma are magnitudes lower [56]. Strikingly, however, the unbound concentrations are iden-
tical [57]. Therefore, throughout the work, we assumed, according to the ‘free drug hypothesis’
[58] that the unbound concentrations in plasma and at the target site coincide, where the latter
exerts the antiviral effect [59, 60]. All analyzed NNRTIs, InIs and PIs, except for raltegravir
(RAL), are highly lipophilic, enabling the unbound drug to rapidly cross cellular membranes,
generating an equilibrium between the unbound drug on either side of the cellular membrane
[61]. Even for the weakly lipophilic compound raltegravir, intracellular concentrations are
proportional to plasma concentrations by a factor precisely resembling their unbound moiety
[62, 63], strongly arguing for the validity of the ‘free drug hypothesis’ for all analyzed drugs.
However, ultimate proof in terms of local measurements in humans are lacking currently and
may be difficult to obtain experimentally. On the contrary, nucleoside reverse transcriptase
inhibitors (NRTIs), which we analysed in a previous work [18] are not expected to obey the
‘free drug hypothesis’ [17, 30, 64]. These compounds need to be actively taken up by cells and
converted intracellularly into pharmacologically active triphosphates (NRTI-TP). Since the
expression of transporters and intracellular enzymes is likely cell-specific, different cell types
may contain vastly different concentrations of pharmacologically active compound. It is
therefore entirely unclear what relevance concentration measurements of NRTI-TPs in tissue
homogenates [65] (containing HIV target- and non-target cells) from sites of viral exposure
(e.g. cervix, rectum) have in terms of prophylaxis.
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Utilising the virus exposure model Eqs (23) and (24), we estimated the probability of virus
clearance (and the prophylactic efficacy φ) as a function of the number of viruses ultimately
reaching a target cell environment, and not as a function of mucosal exposure. The quantita-
tive role of a number of physiological processes underlying primary infection is currently not
fully resolved and impossible to measure in humans (e.g. the cells involved at the local site of
exposure, their abundance, locations, their capabilities to transduce virus through physiologi-
cal barriers and the respective R0s). It is known however, that the virus has to overcome a num-
ber of physiological bottlenecks/barriers to reach a compartment that permits viral expansion.
Despite the mucosal barrier, the sub-mucosal target cell density might initially be low [66],
such that only a tiny fraction of viruses find a target cell before being cleared. It has also been
reported [66–68], that target cells are subsequently recruited to the site of initial exposure due
to inflammation and seminal exposure, mitigating the ‘low target cell bottleneck’ subsequently.
If the low target-cell bottleneck is only prevalent during the first replication cycle it can also be
modelled by simply considering a smaller virus inoculum that reaches a target-cell environ-
ment. In our approach, to obviate model- and parameter uncertainties, we chose a minimal/
parsimoneous, data-driven approach that treats all physiological barriers as a single bottleneck
lumped in terms of the ‘success probability’ r in Eq (24).
The target cell environment herein is a compartment that is decisive for establishing- and
shedding infection (this compartment requires R0 > 1). We also assumed that this compart-
ment is well-perfused at the time scale of interest. Under this assumption, viral kinetic parame-
ters measured in plasma coincide with kinetic parameters at the target cell environment, after
converting the deterministic reaction parameters to their respective stochastic counterparts
(Table 1).
Notably, the model (see Methods section) is calibrated [18] to reflect the per-contact infec-
tion risks for typical transmitter virus loads and different modes of sexual exposure (homo-
and heterosexual), but can also be adapted to model intravenous exposure by e.g. injection.
The calibrated virus exposure model [18] (see Methods section) predicts that either none- or a
single infectious virus enter a replication enabling compartment in the majority of hetero-/
homosexual contacts. Thus, we suggest that EC50ð
bVÞ, EC90ð
bVÞ values stated in Table 3 pro-
vide a good proxy for the drug-specific prophylactic potency after sexual exposure to HIV (see
also S4 Text for a comparison). Importantly, we also observed that increasing the inoculum
size decreases the prophylactic efficacy of all drug classes considered (as suggested by increas-
ing EC50 and EC90) and increases the steepness of the concentration prophylaxis profile, Fig 3.
PIs in particular displayed an almost switch-like prophylactic profile in the case of large inocu-
lum sizes. These observations strikingly indicate that preventive target concentrations can
depend on the route of transmission. I.e., intravenous exposure to HIV (larger inoculum sizes
compared to sexual exposure) may require higher concentrations for HIV prevention.
When R0(⌀) is relatively large, we find that our predictions of prophylactic efficacy and
-potency for or CRAs, RTIs and InIs are relatively invariant to parameter changes (compare
Eqs (25)–(30)). However, we find that when considering an extremely broad range of 1.7 <
R0(⌀) < 112 values, as in S2 Text, that the parameters used are rather conservative in the sense
that they disfavour the drugs and may under-predict prophylactic efficacy. With regard to our
work’s aim (screen out candidates based on lack-off-, or uncertain potency) such a conservative
parameter choice should be preferred. For PIs, although highly sensitive to changes R0 (com-
pare Eqs (31) and (32)) the qualitative statements made (the prophylactic potency is less than
suggested by IC50, as well as the steep shape of the concentration-prophylaxis profile) are
unaffected for arbitrary, yet realistic parameters, as analysed in S2 Text. However, in the pro-
vided software tool (www.systems-pharmacology.org/prep-predictor) it is possible to freely
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change all virus dynamics parameters. Notably, Ribero et al. [69] have recently estimated R0�
8 during acute infection (� 10 days after exposure, virus is detectable), which is much lower
than the value used by us R0� 67, which considers viral replication immediately after expo-
sure, in the so-called eclipse phase before virus becomes detectable. Our R0 value is relatively
high because we assume a lower CL (clearance of free virus) during this early phase of infec-
tion, in line with other modelling approaches [14, 33] and in line with the observation that
adaptive immune responses develop only after about 14 days post exposure [70]. However, if
we utilise CL = 23 (1/day), as in Ribero et al. [69], we obtain similar values of R0.
The knowledge of concentration-prophylaxis relationships between drug classes, and for
each component of a particular drug class allows for the intelligent design of PrEP regimens,
including how quickly protection can be achieved after a loading dose and how forgiving the
regimen is towards missed dosing events. In related article [27] we develop a sophisticated
simulation framework that allows to make use of population pharmacokinetic models, to fully
explore inter-individual pharmacokinetics and to assess sensitivity towards dosing, individual
pharmacokinetic variability and timing of viral challenges.
Our model can be adapted or developed in a number of ways. On a technical side, the ana-
lytical solutions provided in the article can be neatly integrated into hybrid stochastic-deter-
ministic algorithms that consider time-varying drug concentrations (pharmacokinetics), as
outlined in an accompanying article [27]. In brief, therein we utilize analytic solutions for the
extinction probability, Eq (22), to define a set of states where extinction is feasible (extinction
simplex). Whenever trajectories leave the extinction simplex, simulations can be stopped and a
hybrid stochastic-deterministic trajectory can be safely classified as an infection event. Regard-
ing applications, the separate impact of treatment as prevention [71] (in the case of the donor)
versus prophylactic efficacy in the exposed individual can be readily simulated by calibrating
the virus load distribution in potential transmitter populations (see ‘exposure model’ in the
Methods section). The effect of PrEP on the transmission of resistance can be estimated by
altering R0(⌀) (the fitness cost of resistance) and by simultaneously increasing IC50 in Eq (10)
(extent of resistance). The fitness cost of resistance translates into a decreased transmissibility
of resistance in the absence of drugs (Eqs (19)–(21)), while the extent of resistance translates
into an increased transmissibility relative to the wildtype at increasing drug concentrations, as
e.g. illustrated in [18] (Figure 3 therein). Consequently, provided any transmitted resistance
confers some fitness defect, prophylaxis may increase the frequency of transmitted resistance
relative to the wildtype, but not its absolute occurrence [18, 72]. Since resistance to HIV drugs
generally develops in a stepwise manner, the change in EC50 following acquisition of a resis-
tance mutation can be introduced into this model, to identify a zone of selective pressure for
the de novo evolution or spread of resistance under PrEP. However, during the early events
when the virus infection can still be averted, the population size is too small for resistance to
appear de novo: A single point mutation appears with probability 1 − (1 − μ)k at a particular
base, where μ� 2.2 � 10-5 is the per base mutation rate of HIV during reverse transcription
[73] and k is the number of reverse transcription (= cell infection) events. Thus, de novo resis-
tance can be assumed to appear, if e.g. PrEP had not been taken at the time of exposure, such
that the infection expanded exponentially, and when PrEP is (re-)initiated some time after this
early infection has been established. De novo resistance development in the context of poor
adherence can be modelled in analogy to the work conducted by Rosenbloom et al. [74].
It is well known that the establishment of a latent reservoir is the major barrier to viral
extinction during treatment [75] and this reservoir may be established as early as 3 days post
infection [76, 77]. In the current framework, we computed viral extinction when t!1,
assuming drug concentrations stayed constant. Thus, extinction estimates are not affected
by the inclusion of a long lived cellular compartment. In an accompanying article [27] we
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overcome this assumption, explicitly considering drug pharmacokinetics and e.g. short-course
prophylaxis. In the accompanying article infection of long lived cells are considered as an algo-
rithmic stopping criterium: I.e., whenever long lived cells become infected, viral extinction is
considered infeasible.
In summary, we have developed a mechanistic modelling tool to a priori screen antivirals
for their prophylactic utility. Our approach revealed that in vitro measured drug potency
(IC50, IC90) should not be used directly to identify lower bound effective concentrations in
PrEP trials: With the exception of reverse transcriptase inhibitors, PrEP potency may be less
than in vitro drug potency, i.e. higher concentrations of drug are required for prophylaxis than
suggested by their in vitro potency. Consequently, when clinical trial design is guided by in
vitro drug potency, prophylactic dosing regimen may be selected that attain insufficient con-
centrations to adequately prevent HIV infection.
Instead, we recommend to use the tool provided (www.systems-pharmacology.org/prep-
predictor) to translate in vitro drug potency into prophylactic efficacy. We used the developed
methods to assess the prophylactic utility of all treatment approved antivirals, allowing to rule
out particular candidates by lack-of-, or uncertain prophylactic efficacy. To this end, we pre-
sented results using viral dynamics parameters that may under-predict prophylactic efficacy
(S2 Text). These preliminary screens indicated that darunavir (DRV), efavirenz (EFV), nevira-
pine (NVP), etravirine (ETR) and rilpivirine (RPV) may fully prevent infection at concentra-
tions typically achieved during treatment and with an adequate ‘pharmacokinetic margin’.
Notably, this prediction is robust across a wide range of (uncertain) parameters (S2 Text).
Moreover, we predicted that maraviroc (MVC) and dolutegravir (DTG) can potently prevent
infection, but that these drugs do not provide a comparable ‘pharmacokinetic margin’. Fur-
thermore, predictions for MVC are uncertain with respect to viral dynamics parameters (effi-
cacy may both be over- or underpredicted). A next logical step is to further trim this candidate
set by ruling out compounds with ominous safety profiles, followed by an assessment of differ-
ent dosing (roll-out) schemes.
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